T. Rowe Price Associates
ACHN

T. Rowe Price Associates’s Achillion Pharmaceuticals ACHN Stock Holding History

T. Rowe Price Associates’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,478,326
Closed -$16.5M – 2611
2018
Q3 		$16.5M Sell
4,478,326
-100,747
-2% -$300K ﹤0.01% 1279
2018
Q2 		$13M Sell
4,579,073
-79,883
-2% -$272K ﹤0.01% 1300
2018
Q1 		$17.3M Buy
+4,658,956
New +$15.2M ﹤0.01% 1232
2017
Q4 		– Sell
-25,228
Closed -$113K – 2639
2017
Q3 		$113K Hold
25,228
– – ﹤0.01% 2487
2017
Q2 		$116K Sell
25,228
-44,741
-64% -$180K ﹤0.01% 2466
2017
Q1 		$295K Hold
69,969
– – ﹤0.01% 2267
2016
Q4 		$289K Sell
69,969
-2,931,770
-98% -$15.6M ﹤0.01% 2265
2016
Q3 		$24.3M Sell
3,001,739
-1,865,180
-38% -$15.9M ﹤0.01% 1062
2016
Q2 		$38M Buy
4,866,919
+71,712
+1% +$615K 0.01% 882
2016
Q1 		$37M Buy
4,795,207
+735,088
+18% +$5.38M 0.01% 886
2015
Q4 		$43.8M Buy
4,060,119
+11,900
+0.3% +$108K 0.01% 812
2015
Q3 		$28M Buy
4,048,219
+3,844,716
+1,889% +$31.3M 0.01% 971
2015
Q2 		$1.8M Buy
+203,503
New +$1.92M ﹤0.01% 1611
2014
Q2 		– Sell
-27,400
Closed -$90K – 2558
2014
Q1 		$90K Sell
27,400
-22,600
-45% -$79.1K ﹤0.01% 2443
2013
Q4 		$166K Sell
50,000
-10,700
-18% -$31K ﹤0.01% 2351
2013
Q3 		$183K Sell
60,700
-1,962,700
-97% -$13.5M ﹤0.01% 2295
2013
Q2 		$16.6M Buy
+2,023,400
New +$15.4M ﹤0.01% 1119

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

T. Rowe Price Associates's ACHN Position: Q4 2018 in Review

T. Rowe Price Associates sold out of Achillion Pharmaceuticals (ACHN) in Q4 2018, closing a stake of 4,478,326 shares — an estimated $16.5M sold.

T. Rowe Price Associates first reported a position in ACHN in Q2 2013 and held it in 17 quarters. The position peaked at $43.8M in Q4 2015. 121 funds tracked by Wall St. Rank hold ACHN as of Q4 2018.

  • T. Rowe Price Associates reported no remaining Achillion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • T. Rowe Price Associates sold 4,478,326 Achillion Pharmaceuticals shares in Q4 2018, an estimated $16.5M.
  • T. Rowe Price Associates first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 17 quarters.
  • T. Rowe Price Associates's Achillion Pharmaceuticals position peaked at $43.8M in Q4 2015.
  • 121 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2018.

Based on T. Rowe Price Associates's 13F filing for Q4 2018, filed 14 Feb 2019.